Immunotherapy for Bladder Cancer: Latest Advances and Ongoing Clinical Trials

被引：34

作者：

Grados, Daniela F. Ward ^{[1
]}

Ahmadi, Hamed ^{[1
]}

Griffith, Thomas S. ^{[1
,2
]}

Warlick, Christopher A. ^{[1
,2
]}

机构：

[1] Univ Minnesota, Dept Urol, 2231 6th St SE,3-125 CCRB, Minneapolis, MN 55455 USA

[2] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA

来源：

IMMUNOLOGICAL INVESTIGATIONS | 2022年 / 51卷 / 08期

关键词：

BCG; bladder cancer; checkpoint inhibitors; immune targeted therapy; immunotherapy; BACILLUS-CALMETTE-GUERIN; INTRAVESICAL NADOFARAGENE-FIRADENOVEC; TRANSITIONAL-CELL CARCINOMA; TERM-FOLLOW-UP; SINGLE-ARM; PHASE-III; HIGH-GRADE; UROTHELIAL CARCINOMA; DURVALUMAB MEDI4736; OPEN-LABEL;

D O I：

10.1080/08820139.2022.2118606

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

For nearly 50 years, immunotherapy has been used in patients with bladder cancer in the form of Mycobacterium bovis Bacillus Calmette-Guerin (BCG), which is still the first-line therapy for non-muscle invasive disease. However, the remarkable results obtained with checkpoint inhibitor drugs, including Pembrolizumab and Atezolizumab, have fueled the quest to optimize these and other forms of immunotherapy for both non-muscle invasive as well as advanced bladder cancer. In this review we summarize the current state of the rapidly evolving field of immunotherapy in bladder cancer highlighting novel approaches and ongoing trials in this exciting area of research.

引用

页码：2226 / 2251

页数：26

共 83 条

[1] The Evolving Landscape of Antibody-Drug Conjugates for Urothelial Carcinoma [J].

Abel, Melissa ;

Burkenroad, Aaron ;

Sun, Alexander ;

Lu, Eric ;

Stefanoudakis, Dimitrios ;

Drakaki, Alexandra .

CLINICAL GENITOURINARY CANCER, 2021, 19 (03) :183-193

[2] CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma [J].

Advani, Ranjana ;

Flinn, Ian ;

Popplewell, Leslie ;

Forero, Andres ;

Bartlett, Nancy L. ;

Ghosh, Nilanjan ;

Kline, Justin ;

Roschewski, Mark ;

LaCasce, Ann ;

Collins, Graham P. ;

Thu Tran ;

Lynn, Judith ;

Chen, James Y. ;

Volkmer, Jens-Peter ;

Agoram, Balaji ;

Huang, Jie ;

Majeti, Ravindra ;

Weissman, Irving L. ;

Takimoto, Chris H. ;

Chao, Mark P. ;

Smith, Sonali M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (18) :1711-1721

[3] Perioperative Intravesical Chemotherapy in Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis [J].

Ahern, Michael R. ;

Owusu, Richmond A. ;

Anderson, Mark R. ;

Rampersaud, Edward N. ;

Inman, Brant A. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (04) :477-484

[4] Diagnosis and Staging of Bladder Cancer [J].

Ahmadi, Named ;

Duddalwar, Vinay ;

Daneshmand, Siamak .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2021, 35 (03) :531-541

[5] Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder [J].

Al-Obaidy, Khaleel, I ;

Cheng, Liang .

JOURNAL OF CLINICAL PATHOLOGY, 2021, 74 (08) :491-495

[6] Phase I trial of intravesical Bacillus Calmette-Guerin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guerin treatment [J].

Alanee, Shaheen ;

Sana, Sherjeel ;

El-Zawahry, Ahmed ;

Peabody, James ;

Pearce, Tiffany ;

Adams, Nicole ;

Deebajah, Mustafa ;

Crabtree, Jane ;

Delfino, Kristin ;

McVary, Kevin ;

Robinson, Kathy ;

Rao, Krishna .

WORLD JOURNAL OF UROLOGY, 2021, 39 (10) :3807-3813

[7] Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC) [J].

Alvarez-Maestro, M. ;

Guerrero-Ramos, F. ;

Rodriguez-Faba, O. ;

Dominguez-Escrig, J. L. ;

Fernandez-Gomez, J. M. .

ACTAS UROLOGICAS ESPANOLAS, 2021, 45 (02) :93-102

[8]

Babjuk MC., 2022, PRESENTED EAU ANN C

[9] Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study [J].

Balar, Arjun, V ;

Kamat, Ashish M. ;

Kulkarni, Girish S. ;

Uchio, Edward M. ;

Boormans, Joost L. ;

Roumiguie, Mathieu ;

Krieger, Laurence E. M. ;

Singer, Eric A. ;

Bajorin, Dean F. ;

Grivas, Petros ;

Seo, Ho Kyung ;

Nishiyama, Hiroyuki ;

Konety, Badrinath R. ;

Li, Haojie ;

Nam, Kijoeng ;

Kapadia, Ekta ;

Frenkl, Tara ;

de Wit, Ronald .

LANCET ONCOLOGY, 2021, 22 (07) :919-930

[10] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].

Balar, Arjun V. ;

Galsky, Matthew D. ;

Rosenberg, Jonathan E. ;

Powles, Thomas ;

Petrylak, Daniel P. ;

Bellmunt, Joaquim ;

Loriot, Yohann ;

Necchi, Andrea ;

Hoffman-Censits, Jean ;

Perez-Gracia, Jose Luis ;

Dawson, Nancy A. ;

van der Heijden, Michiel S. ;

Dreicer, Robert ;

Srinivas, Sandy ;

Retz, Margitta M. ;

Joseph, Richard W. ;

Drakaki, Alexandra ;

Vaishampayan, Ulka N. ;

Sridhar, Srikala S. ;

Quinn, David I. ;

Duran, Ignacio ;

Shaffer, David R. ;

Eigl, Bernhard J. ;

Grivas, Petros D. ;

Yu, Evan Y. ;

Li, Shi ;

Kadel, Edward E., III ;

Boyd, Zachary ;

Bourgon, Richard ;

Hegde, Priti S. ;

Mariathasan, Sanjeev ;

Thastrom, AnnChristine ;

Abidoye, Oyewale O. ;

Fine, Gregg D. ;

Bajorin, Dean F. .

LANCET, 2017, 389 (10064) :67-76

← 1 2 3 4 5 6 7 8 9 →